ArriVent Biopharma

Founded 2021 · CIK 0001868279 · Biotech · Public

Furmonertinib, an EGFR inhibitor small-molecule therapeutic for non-small cell lung cancer with enhanced blood-brain barrier penetration

arrivent.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$191M
2 Form D · Dec 2022
45 months since last filing
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$81,000,000
Private capital raisedForm D · SEC$109,999,989
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2221Pheast Therapeutics—$50M
2222Tmunity Therapeutics—$140M
2223Alloy Therapeutics—$147M
2224ArriVent Biopharma—$191M
2225MOBIUS SCIENTIFIC INC.——
2226PMV Pharmaceuticals—$74M
2227FibroBiologics, LLC—$11M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 7 related persons
  • Carl GordonDirector
  • James HealyDirector
  • Bahija JallalDirector
  • Stuart LutzkerDirector
  • Cong XuDirector
  • Zhengbin (Bing) YaoDirector · Executive Officer
  • Jason ZhangDirector

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.